SciTech Development, Inc.

GROSSE POINTE FARMS, MI · CIK 0001682585 · Biotech · Private

Nanoparticle drug delivery platform for cancer therapeutics, with lead candidate ST-001 nanoFenretinide

scitechdevelopment.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$470K
6 Form D · Oct 2024
24 months since last filing
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,000,000
Private capital raisedForm D · SEC$124,538
Private capital raisedForm D · SEC$105,000
Private capital raisedForm D · SEC$2,000,000
Private capital raisedForm D · SEC$3,000,000
Private capital raisedForm D · SEC$240,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1828NMN Holdings LP——
1829Reven Pharmaceuticals, Inc.—$23K
1830Harton, Inc.—$15M
1831SciTech Development, Inc.—$470K
1832Habelo Beauty, LLC—$25K
1833Monument Enterprises USA LLC—$250K
1834DOUBLE LUCKY BIOPHARM, LTD——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Michael BurnsExecutive Officer · Promoter
  • Earl HolsappleDirector · Executive Officer · Promoter
  • Earle HolsappleDirector · Executive Officer · Promoter
  • Lou ScarmoutzosExecutive Officer
  • Andrew StumpfExecutive Officer
  • Don ZinnExecutive Officer

Patents

USPTO · 0 granted of 2
  • Fenretinide Formulationsapplication
  • Fenretinide Formulationsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.